MedTrace Logo

Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast

NCT00664534 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 344

Last updated 2011-12-13

Study results available
· View outcomes & findings →

Summary

This study is designed to look at how best to start and then gradually intensify (as needed) the insulin lispro premix regimen in type 2 diabetes patients who consume a light breakfast.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Glargine

patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks

DRUG

Insulin Lispro Premix (mid-mixture and low-mixture)

patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 am-5 pm Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Canada
  • Egypt
  • India
  • Mexico
  • Portugal
  • Romania
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664534 on ClinicalTrials.gov